PMDD (Premenstrual Dysphoric Disorder): Understanding and Management

What Is PMDD?

PMDD is a severe, cyclic mood disorder affecting ~3–8% of menstruating women. Symptoms occur in the luteal phase (post-ovulation), resolve within days of menses, and cause marked functional impairment.

Diagnostic Criteria (DSM-5-TR)

≥5 symptoms in most cycles, including ≥1 core mood symptom:

  • Core mood: Marked irritability/anger, depressed mood/hopelessness, marked anxiety/tension, marked affective lability.
  • Additional: Decreased interest, concentration difficulty, fatigue, appetite changes, hypersomnia/insomnia, feeling overwhelmed, physical symptoms (breast tenderness, bloating, headache).

Etiology

  • Abnormal sensitivity to normal hormonal fluctuations (estradiol, progesterone) → altered serotonin/GABA signaling.
  • Genetic predisposition (ESR1, BDNF variants).
  • Trauma/stress history increases vulnerability.

Treatment (Stepped Approach)

  • First-line: SSRIs (continuous or luteal-phase only) — fluoxetine, sertraline, paroxetine, escitalopram. Response in days (not weeks like depression).
  • Hormonal: Combined OCP with drospirenone (Yaz® FDA-approved for PMDD); GnRH agonists + add-back (severe).
  • Lifestyle: Calcium 1200 mg, vitamin D, B6, magnesium, aerobic exercise, CBT, stress reduction.
  • Supplements: Vitex agnus-castus (chasteberry) — modest evidence.

No Known Prevention

But early recognition and treatment dramatically improve quality of life. Track symptoms × 2 cycles for diagnosis. Advocate for referral to women's mental health or reproductive psychiatry specialist.

Genetic Disorders - Related Articles